Arcus Biosciences reports casdatifan kidney cancer data with nearly 3-year median overall survival in heavily pretreated patients

Arcus Biosciences reported casdatifan kidney cancer data showing nearly three-year median overall survival in heavily pretreated patients. Phase 3 trials remain pending.

Detected & updated continuously · Source: Nebula